Conflict of Interest
tumors, Cancer
FABER, ONCOLOGY, TUMORS, PLUMMER, CANCER
Matthew G. Krebs declares to have received honoraria from Roche, has a consulting or advisory role at Roche, Achilles Therapeutics, Janssen, Seattle Genetics, OM Pharma, Bayer, Guardant Health, speakers’ bureau at Roche, Janssen, received research funding from Roche (Inst) and expenses for travel and accommodations from AstraZeneca, BerGenBio, and Immutep. Ruth Plummer declares to have received Honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Immunocore, Genmab, Astex Therapeutics, Medivir, and Sanofi Aventis, and honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo and SOTIO Biotech AG, AstraZeneca, payment for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer and BMS, and funds to support attendance at conferences from MSD and BMS. Filip De Vos declares to have received grants from foundationstopbraintumors.org, BMS, Novartis, and EORTC, is a faculty member of ESMO CNS tumors, and is part of the Quality of Care Commission Dutch Society of Medical Oncology and Quality Assurance Commission EORTC. Eric Angevin declares to have received fees from Merck Sharp & Dohme, GlaxoSmithKline, Celgene Research, MedImmune, and Roche, has patents planned at AbbVie, Roche, Sanofi, Pfizer, and MedImmune, and participates at an advisory board for MedImmune and Roche. Hans Prenen declares to have received honoraria for lectures from Amgen, Roche, and Sanofi and support for attending meetings from Ipsen and Roche. Martin D. Forster declares to have received grants from Cancer Research UK Early Detection Committee Program Grant, Bristol Myers Squibb Research Grant, NIHR RfPB Grant, Cancer Research UK Science Committee Multidisciplinary Project Award, Merck Educational Grant, MSD Educational Grant, Cancer Research UK Science Committee Multidisciplinary Project Award, and MRC BMC:DPFS Grant Award. Glen Clack declared to have received support from AstraZeneca, Carrick Therapeutics Ltd., Athenex Inc., Evgen Plc, and Ailse Oncology Ltd., and has a patent for Docket No. 201026-US-PSP